Skip to main content
. 2019 Nov 7;9(1):1684714. doi: 10.1080/2162402X.2019.1684714

Figure 5.

Figure 5.

Strong dLN neo-antigen responses to UNC45a predict combination ICPB outcomes.

a. Schema of treatment and surgery. b. Bilateral tumor growth curve over time. Arrows represent surgery and treatment time (n = 22). Responses to therapy are depicted by black solid lines. Pre-treatment reactivity to c. mutant UQCRC2, and d. mutant UNC45a in the dLN of responders (n = 12) and non-responders (n = 10). Student’s T-test; error bars mean ± SD.